URGN vs. PGEN, MREO, VTYX, RANI, NLTX, EPIX, ENTA, NATR, ATAI, and FBLG
Should you be buying UroGen Pharma stock or one of its competitors? The main competitors of UroGen Pharma include Precigen (PGEN), Mereo BioPharma Group (MREO), Ventyx Biosciences (VTYX), Rani Therapeutics (RANI), Neoleukin Therapeutics (NLTX), ESSA Pharma (EPIX), Enanta Pharmaceuticals (ENTA), Nature's Sunshine Products (NATR), Atai Life Sciences (ATAI), and FibroBiologics (FBLG). These companies are all part of the "pharmaceutical preparations" industry.
UroGen Pharma (NASDAQ:URGN) and Precigen (NASDAQ:PGEN) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their valuation, dividends, profitability, institutional ownership, risk, analyst recommendations, earnings, media sentiment and community ranking.
Precigen received 74 more outperform votes than UroGen Pharma when rated by MarketBeat users. However, 73.13% of users gave UroGen Pharma an outperform vote while only 67.03% of users gave Precigen an outperform vote.
UroGen Pharma presently has a consensus target price of $46.67, indicating a potential upside of 224.75%. Precigen has a consensus target price of $10.00, indicating a potential upside of 624.64%. Given Precigen's higher possible upside, analysts clearly believe Precigen is more favorable than UroGen Pharma.
UroGen Pharma has a beta of 1.07, meaning that its share price is 7% more volatile than the S&P 500. Comparatively, Precigen has a beta of 1.73, meaning that its share price is 73% more volatile than the S&P 500.
91.3% of UroGen Pharma shares are owned by institutional investors. Comparatively, 33.5% of Precigen shares are owned by institutional investors. 11.1% of UroGen Pharma shares are owned by insiders. Comparatively, 41.7% of Precigen shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Precigen has lower revenue, but higher earnings than UroGen Pharma. UroGen Pharma is trading at a lower price-to-earnings ratio than Precigen, indicating that it is currently the more affordable of the two stocks.
UroGen Pharma has a net margin of -123.61% compared to Precigen's net margin of -1,540.63%. UroGen Pharma's return on equity of 0.00% beat Precigen's return on equity.
In the previous week, UroGen Pharma had 7 more articles in the media than Precigen. MarketBeat recorded 7 mentions for UroGen Pharma and 0 mentions for Precigen. UroGen Pharma's average media sentiment score of 0.40 beat Precigen's score of 0.00 indicating that UroGen Pharma is being referred to more favorably in the media.
Summary
Precigen beats UroGen Pharma on 9 of the 17 factors compared between the two stocks.
Get UroGen Pharma News Delivered to You Automatically
Sign up to receive the latest news and ratings for URGN and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding URGN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
UroGen Pharma Competitors List
Related Companies and Tools
